RT Journal Article
SR Electronic
T1 A machine learning-based model for survival prediction in patients with severe COVID-19 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.27.20028027
DO 10.1101/2020.02.27.20028027
A1 Yan, Li
A1 Zhang, Hai-Tao
A1 Goncalves, Jorge
A1 Xiao, Yang
A1 Wang, Maolin
A1 Guo, Yuqi
A1 Sun, Chuan
A1 Tang, Xiuchuan
A1 Jin, Liang
A1 Zhang, Mingyang
A1 Huang, Xiang
A1 Xiao, Ying
A1 Cao, Haosen
A1 Chen, Yanyan
A1 Ren, Tongxin
A1 Wang, Fang
A1 Xiao, Yaru
A1 Huang, Sufang
A1 Tan, Xi
A1 Huang, Niannian
A1 Jiao, Bo
A1 Zhang, Yong
A1 Luo, Ailin
A1 Mombaerts, Laurent
A1 Jin, Junyang
A1 Cao, Zhiguo
A1 Li, Shusheng
A1 Xu, Hui
A1 Yuan, Ye
YR 2020
UL http://medrxiv.org/content/early/2020/03/17/2020.02.27.20028027.abstract
AB The sudden increase of COVID-19 cases is putting a high pressure on healthcare services worldwide. At the current stage, fast, accurate and early clinical assessment of the disease severity is vital. To support decision making and logistical planning in healthcare systems, this study leverages a database of blood samples from 404 infected patients in the region of Wuhan, China to identify crucial predictive biomarkers of disease severity. For this purpose, machine learning tools selected three biomarkers that predict the survival of individual patients with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). In particular, relatively high levels of LDH alone seem to play a crucial role in distinguishing the vast majority of cases that require immediate medical attention. This finding is consistent with current medical knowledge that high LDH levels are associated with tissue breakdown occurring in various diseases, including pulmonary disorders such as pneumonia. Overall, this paper suggests a simple and operable formula to quickly predict patients at the highest risk, allowing them to be prioritised and potentially reducing the mortality rate.Funding None.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available once the paper gets accepted. The Python code is available upon request from YY.